https://www.ophthalmologytimes.com/view/detecting-peripheral-retinal-lesions-in-children-with-myopia 2026-06-26 0.50 https://www.ophthalmologytimes.com/view/optimizing-anti-vegf-in-amd-dme-and-rvo-strategies-for-durable-disease-control 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/phase-3-data-support-otx-tki-s-durability-in-wet-amd-1-injection-1-year 2026-06-29 0.50 https://www.ophthalmologytimes.com/view/viridian-therapeutics-lumvoa-receives-fda-approval-for-thyroid-eye-disease-across-active-and-chronic-stages 2026-06-29 0.50 https://www.ophthalmologytimes.com/view/digital-mindfulness-app-reduces-anxiety-depression-in-uveitis 2026-06-27 0.50 https://www.ophthalmologytimes.com/view/the-wills-retina-report-regillo-and-garg-on-managing-geographic-atrophy-who-when-and-how 2026-06-26 0.50 https://www.ophthalmologytimes.com/view/seeing-what-visual-acuity-misses-focal-microperimetry-in-geographic-atrophy 2026-06-25 0.50 https://www.ophthalmologytimes.com/view/eichenbaum-acorns-from-clinic-to-c-suite-with-jay-s-duker-md-and-ramiro-ribeiro-md-phd 2026-06-19 0.50 https://www.ophthalmologytimes.com/view/iprgc-sleep-circadian-rhythms-alzheimers-disease 2026-06-16 0.50 https://www.ophthalmologytimes.com/view/stemsight-patent-limbal-stem-cell-ste-101 2026-06-16 0.50 https://www.ophthalmologytimes.com/view/cts-2026-otx-tki-aflibercept-wet-amd-sol-1-data 2026-06-15 0.50 https://www.ophthalmologytimes.com/view/ranluspec-fda-approval-cyrus-karkaria-biosimilar-prefilled-syringes 2026-06-11 0.50 https://www.ophthalmologytimes.com/view/geographic-atrophy-when-lesion-borders-cannot-be-graded 2026-06-13 0.50 https://www.ophthalmologytimes.com/view/phase-3-northstar-trial-launches-for-gildeuretinol-in-stargardt-disease 2026-06-11 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-career-and-community-with-david-eichenbaum-md 2026-06-11 0.50 https://www.ophthalmologytimes.com/view/fda-guidance-to-help-accelerate-cell-and-gene-therapies 2026-06-10 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-at-the-summit-2026-first-time-data-ai-and-the-next-generation-of-retinal-treatments 2026-06-10 0.50 https://www.ophthalmologytimes.com/view/fda-approves-ranibizumab-hkdz-interchangeable-biosimilar 2026-06-11 0.50 https://www.ophthalmologytimes.com/view/hpv-and-uveitis-new-research-points-to-a-potential-connection 2026-06-15 0.50 https://www.ophthalmologytimes.com/view/q-a-peripheral-vision-iol-s-influence-on-driving-performance 2026-06-09 0.50 https://www.ophthalmologytimes.com/view/thn391-enters-phase-1b-trial-for-diabetic-macular-edema 2026-06-01 0.50 https://www.ophthalmologytimes.com/view/our-humble-genome 2026-05-29 0.50 https://www.ophthalmologytimes.com/view/q-a-evaluating-24-month-outcomes-with-abiliti-1-day-in-pediatric-myopia-control 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/phase-3-data-support-otx-tki-s-durability-in-wet-amd-one-injection-one-year 2026-06-09 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-the-dopamine-amd-connection 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-dry-amd-geographic-atrophy-photobiomodulation-and-the-road-ahead 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-port-delivery-system-shows-durable-outcomes-at-7-years-in-neovascular-amd 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-expanding-the-dme-treatment-algorithm-beyond-anti-vegf 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/q-a-using-natural-images-for-the-evaluation-of-distance-image-quality-in-iols 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/uveai-automated-fluorescein-angiography-scoring-for-retinal-inflammation-in-uveitis 2026-05-29 0.50 https://www.ophthalmologytimes.com/view/rwc-2026-rvo-systemic-vascular-health 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/geographic-atrophy-topography-what-the-central-2-5-mm-region-reveals 2026-05-29 0.50 https://www.ophthalmologytimes.com/view/fda-grants-appeal-for-bevacizumab-vikg-bla-in-neovascular-amd 2026-05-29 0.50 https://www.ophthalmologytimes.com/view/preclinical-study-explores-contact-lens-based-neuromodulation-for-depression 2026-05-27 0.50 https://www.ophthalmologytimes.com/view/mactel-masquerades-how-to-spot-what-others-miss 2026-06-08 0.50 https://www.ophthalmologytimes.com/view/qa102-data-suggest-signal-in-intermediate-dry-amd-but-insignificant-drusen-volume-change 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/no-smoking-gun-oct-biomarker-found-for-dme-outcomes-insights-from-protocol-t 2026-05-22 0.50 https://www.ophthalmologytimes.com/view/avacincaptad-pegol-analysis-links-ga-treatment-to-preserved-driving-vision 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/tinlarebant-earns-swiss-orphan-drug-status-for-stargardt-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-eyp-1901-phase-2-updates-for-wet-amd-and-dme 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/biogen-completes-acquisition-of-apellis-pharmaceuticals 2026-05-22 0.50 https://www.ophthalmologytimes.com/view/intracortical-visual-prosthesis-a-new-chapter-in-advancing-visual-restoration 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-rethinking-macular-hole-surgery-without-gas-tamponade 2026-05-17 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-identifying-real-world-durability-gaps-in-wet-amd-treatment 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/can-vibration-reduce-pain-during-intravitreal-injections 2026-05-16 0.50 https://www.ophthalmologytimes.com/view/sunir-j-garg-md-facs-on-preventing-occupational-injury-in-retina-practice 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/diagnosing-macular-telangiectasia-in-a-field-of-mimickers 2026-06-08 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-the-case-for-earlier-surgical-intervention-in-diabetic-macular-edema 2026-05-15 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-2026-uveitis-risk-rises-as-immune-checkpoint-inhibitor-use-expands 2026-05-14 0.50 https://www.ophthalmologytimes.com/view/laru-zova-sustains-visual-function-improvements-at-12-months-in-xlrp-gene-therapy-trial 2026-06-02 0.50 https://www.ophthalmologytimes.com/view/navigating-the-ocular-risks-of-facial-fillers-with-jennifer-murdock-md 2026-05-11 0.50 https://www.ophthalmologytimes.com/view/beyond-anti-vegf-the-next-wave-in-retinal-therapy 2026-06-24 0.50 https://www.ophthalmologytimes.com/view/condor-clinical-trial-brolucizumab-superior-to-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy 2026-04-29 0.50 https://www.ophthalmologytimes.com/view/belite-bio-initiates-rolling-nda-submission-for-tinlarebant-in-stargardt-disease-type-1 2026-04-28 0.50 https://www.ophthalmologytimes.com/view/additional-sol-1-analyses-show-delayed-csft-worsening-with-axpaxli 2026-04-24 0.50 https://www.ophthalmologytimes.com/view/eichenbaum-acorns-paying-it-forward-with-christina-y-weng-md-mba-fasrs 2026-06-11 0.50 https://www.ophthalmologytimes.com/view/oculis-completes-final-patient-visit-in-ocs-01-phase-3-trial-in-dme 2026-04-21 0.50 https://www.ophthalmologytimes.com/view/chemoplaque-therapy-for-retinoblastoma-a-potentially-novel-more-accessible-treatment-approach 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/the-retina-tl-dr-with-dr-weng-unpacking-photobiomodulation-for-dry-amd 2026-04-16 0.50 https://www.ophthalmologytimes.com/view/eclipse-life-sciences-completes-enrollment-in-bettis-1-phase-2-clinical-trial 2026-04-13 0.50 https://www.ophthalmologytimes.com/view/new-tried-and-true-treatments-for-retinal-vein-occlusion 2026-04-10 0.50 https://www.ophthalmologytimes.com/view/fda-expands-faricimab-label-to-include-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-beyond-6-months 2026-04-10 0.50 https://www.ophthalmologytimes.com/view/ocugen-completes-dosing-early-in-phase-2-3-gardian3-trial-for-stargardt-disease 2026-04-03 0.50 https://www.ophthalmologytimes.com/view/tattoo-associated-uveitis-an-emerging-eye-health-challenge 2026-04-07 0.50 https://www.ophthalmologytimes.com/view/directional-oct-provides-biomarkers-of-parkinson-s-disease-in-the-outer-retina 2026-04-02 0.50 https://www.ophthalmologytimes.com/view/fda-grants-rmat-designation-to-rtx-015-optogenetic-gene-therapy-for-retinitis-pigmentosa 2026-04-07 0.50 https://www.ophthalmologytimes.com/view/merck-launches-phase-2b-3-malbec-trial-of-mk-8748-in-wet-amd 2026-04-06 0.50 https://www.ophthalmologytimes.com/view/oln324-shows-comparable-vision-gains-potential-durability-advantage-vs-faricimab-in-phase-1b-wamd-dme-study 2026-03-31 0.50 https://www.ophthalmologytimes.com/view/fda-approves-extended-dosing-intervals-up-to-20-weeks-for-eylea-hd-in-wamd-and-dme 2026-04-06 0.50 https://www.ophthalmologytimes.com/view/getting-to-the-root-of-geographic-atrophy-diagnosis-and-management 2026-03-30 0.50 https://www.ophthalmologytimes.com/view/first-patient-dosed-in-phase-i-ii-trial-of-complement-targeting-gene-therapy-for-geographic-atrophy 2026-04-01 0.50 https://www.ophthalmologytimes.com/view/taking-a-step-beyond-low-vision-aids-to-sharpen-the-focus-on-visual-rehabilitation 2026-03-30 0.50 https://www.ophthalmologytimes.com/view/aflibercept-to-treat-rop-in-extremely-low-birth-weight-children 2026-03-30 0.50 https://www.ophthalmologytimes.com/view/multi-luminance-shape-discrimination-test-shows-reliability-in-low-vision-rp-population 2026-03-27 0.50 https://www.ophthalmologytimes.com/view/phase-2-topline-data-ocugen-ocu410-reduces-geographic-atrophy-lesion-growth-by-31-at-12-months 2026-03-24 0.50 https://www.ophthalmologytimes.com/view/the-retina-tl-dr-with-dr-weng-moving-beyond-anti-vegf-with-otx-tki-and-pravin-u-dugel-md 2026-03-23 0.50 https://www.ophthalmologytimes.com/view/onl-therapeutics-randomizes-first-european-patient-in-phase-2-ga-trial-of-xelafaslatide 2026-03-16 0.50 https://www.ophthalmologytimes.com/view/genetic-retinoblastoma-risk-stratified-by-age-among-patients-with-metachronous-bilateral-conversion 2026-03-13 0.50 https://www.ophthalmologytimes.com/view/galimedix-therapeutics-earns-milestone-payment-in-ophthalmology-partnership-with-th-a-open-innovation 2026-03-13 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-drug-shortages-more-frequent-longer-lasting-than-average 2026-03-13 0.50 https://www.ophthalmologytimes.com/view/johnson-johnson-s-tecnis-puresee-edof-iol-cleared-for-us-market 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eichenbaum-acorns-collaborative-retina-care-with-jeffrey-gerson-od 2026-03-11 0.50 https://www.ophthalmologytimes.com/view/novabridge-visara-report-positive-phase-2a-results-for-dual-vegf-a-ang-2-inhibitor-vis-101 2026-03-10 0.50 https://www.ophthalmologytimes.com/view/fda-clears-phase-i-ii-trial-of-svt-001-cell-therapy-for-familial-drusen-associated-vision-loss 2026-03-10 0.50 https://www.ophthalmologytimes.com/view/ocugen-completes-enrollment-in-limelight-phase-3-trial-of-ocu400-for-retinitis-pigmentosa 2026-03-10 0.50 https://www.ophthalmologytimes.com/view/pegcetacoplan-does-not-impact-anti-vegf-treatment-in-geographic-atrophy-with-ted-leng-md-ms 2026-03-03 0.50 https://www.ophthalmologytimes.com/view/eylea-8mg-in-rvo-quasar-clinical-perspectives-video 2026-03-03 0.50 https://www.ophthalmologytimes.com/view/eylea-8mg-in-rvo-snapshot-of-the-64-week-quasar-data 2026-03-03 0.50 https://www.ophthalmologytimes.com/view/q-a-ai-predicted-retinal-function-shows-promise-in-geographic-atrophy 2026-02-24 0.50 https://www.ophthalmologytimes.com/view/dr-mali-s-top-5-predictions-in-ophthalmology-for-2026 2026-02-24 0.50 https://www.ophthalmologytimes.com/view/the-retina-tl-dr-with-dr-weng-tracking-retinal-gene-therapies-with-arshad-m-khanani-md-ma-fasrs 2026-02-24 0.50 https://www.ophthalmologytimes.com/view/gennady-landa-md-shares-clinical-insights-on-the-ranibizumab-ocular-implant 2026-02-20 0.50 https://www.ophthalmologytimes.com/view/samsung-bioepis-reaches-settlement-agreement-for-eylea-aflibercept-biosimilar 2026-02-16 0.50 https://www.ophthalmologytimes.com/view/iss-2026-highlights-advances-in-ophthalmic-imaging-for-retinal-practice 2026-02-14 0.50 https://www.ophthalmologytimes.com/view/american-college-of-physicians-policy-paper-urges-medical-community-to-drop-the-term-provider- 2026-02-10 0.50 https://www.ophthalmologytimes.com/view/prima-system-a-major-step-in-the-battle-against-ga 2026-02-09 0.50 https://www.ophthalmologytimes.com/view/meiragtx-licenses-complement-targeted-geographic-atrophy-program-from-zipbio 2026-02-09 0.50 https://www.ophthalmologytimes.com/view/metformin-use-associated-with-reduced-incidence-of-intermediate-amd 2026-02-09 0.50 https://www.ophthalmologytimes.com/view/fda-decision-carbachol-brimonidine-ophthalmic-solution-approved-for-presbyopia-following-brio-phase-3-results 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/new-optoretinography-technique-allows-direct-measurement-of-rod-function-in-vivo 2026-01-09 0.50 https://www.ophthalmologytimes.com/view/navigating-geographic-atrophy-from-biomarkers-to-bilateral-therapy 2026-02-26 0.50 https://www.ophthalmologytimes.com/view/ollin-biosciences-reports-positive-head-to-head-phase-1b-data-for-oln324-vs-faricimab 2026-01-09 0.50 https://www.ophthalmologytimes.com/view/eichenbaum-acorns-mentorship-momentum-and-the-making-of-a-retina-podcast 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/long-lived-greenland-sharks-may-point-to-new-approaches-for-retinal-disease 2026-01-07 0.50 https://www.ophthalmologytimes.com/view/molecular-insights-and-clinical-experience-extending-anti-vegf-durability 2026-01-05 0.50 https://www.ophthalmologytimes.com/view/q-a-evolving-approaches-to-geographic-atrophy-management 2026-01-15 0.50 https://www.ophthalmologytimes.com/view/nanoscope-secures-new-us-patent-for-multi-characteristic-opsin-mco-technology-platform 2026-01-09 0.50 https://www.ophthalmologytimes.com/view/rates-of-retinal-layer-thinning-predict-visual-field-progression-in-glaucoma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/exploring-emerging-therapies-in-the-retinal-vascular-disease-pipeline 2026-01-13 0.50 https://www.ophthalmologytimes.com/view/the-retina-tl-dr-with-dr-weng-targeting-the-fas-signaling-pathway-with-david-zacks-md-phd 2026-01-13 0.50 https://www.ophthalmologytimes.com/view/first-patient-treated-in-dose-expansion-portion-of-splicebio-s-phase-1-2-astra-clinical-trial 2026-01-09 0.50 https://www.ophthalmologytimes.com/view/fda-grants-fast-track-designation-to-complement-therapeutics-ctx001-for-geographic-atrophy 2026-01-12 0.50 https://www.ophthalmologytimes.com/view/8-things-to-know-about-aflibercept-8-mg-for-retinal-vascular-disease 2026-02-26 0.50 https://www.ophthalmologytimes.com/view/a-new-treatment-round-up-for-amd-and-ga 2026-01-07 0.50 https://www.ophthalmologytimes.com/view/floretina-inadvertent-anti-vegf-interval-increases-during-the-covid-19-pandemic 2025-12-22 0.50 https://www.ophthalmologytimes.com/view/primavera-study-central-vision-improvement-with-subretinal-implant 2026-01-07 0.50 https://www.ophthalmologytimes.com/view/staar-surgical-terminates-proposed-acquisition-by-alcon 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/macular-laser-picks-up-speed-the-technology-accelerating-retinal-therapies 2025-12-12 0.50 https://www.ophthalmologytimes.com/view/evaluating-safety-and-clinical-confidence-between-aflibercept-8-mg-and-2-mg-in-retinal-vascular-diseases 2026-01-06 0.50 https://www.ophthalmologytimes.com/view/management-approaches-for-suboptimal-responders-in-amd-dme-and-rvo 2026-01-06 0.50 https://www.ophthalmologytimes.com/view/treating-mactel-first-identify-patient-candidates-and-appropriate-eye-selection 2026-06-08 0.50 https://www.ophthalmologytimes.com/view/inside-the-mindset-of-an-early-adopter 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/fda-outlook-therapeutics-complete-response-letter-ons-5010 2025-12-31 0.50 https://www.ophthalmologytimes.com/view/challenges-for-young-physicians-treating-patients-with-ga 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/comparing-aflibercept-8-mg-and-faricimab-in-rvo 2025-12-30 0.50 https://www.ophthalmologytimes.com/view/insights-from-privotal-trials-for-aflibercept-8-mg-in-rvo 2025-12-30 0.50 https://www.ophthalmologytimes.com/view/a-medical-fellow-finds-some-magic-at-the-aao-annual-meeting 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/aao-highlight-looking-ahead-to-2026 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/how-ai-is-reshaping-ophthalmology-in-2025-and-beyond 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/evaluating-retinal-drying-durability-and-iop-management-with-second-generation-anti-vegf-therapies-in-retinal-vascular-diseases 2025-12-23 0.50 https://www.ophthalmologytimes.com/view/loading-dose-adjustments-and-treatment-switching-strategies-in-retinal-vascular-diseases 2025-12-23 0.50 https://www.ophthalmologytimes.com/view/seeing-the-difference-multimodal-imaging-for-amd-and-ga 2026-02-26 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-eu-rop-registry-bridges-borders-for-real-world-insight 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/the-atrophy-advisor-an-online-tool-to-inform-ga-treatment-decisions 2025-12-18 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-updates-on-tinlarebant-in-adolescent-stargardt-disease 2025-12-12 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-long-term-follow-up-in-pediatric-gene-therapy 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/enhancing-durability-and-fluid-control-with-aflibercept-8-mg-in-retinal-vascular-diseases 2025-12-16 0.50 https://www.ophthalmologytimes.com/view/evolving-therapeutic-strategies-with-next-generation-anti-vegf-agents-in-retinal-vascular-diseases 2025-12-16 0.50 https://www.ophthalmologytimes.com/view/timely-interventions-can-protect-vision-in-patients-with-ga 2025-12-11 0.50 https://www.ophthalmologytimes.com/view/aviceda-therapeutics-reports-positive-phase-2b-siglec-results-for-avd-104-in-geographic-atrophy 2025-12-15 0.50 https://www.ophthalmologytimes.com/view/monitoring-mactel-why-bcva-does-not-tell-the-whole-story 2026-06-08 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-accelerates-nda-submission-plans-for-axpaxli-for-wet-amd 2025-12-08 0.50 https://www.ophthalmologytimes.com/view/onl-therapeutics-reports-positive-phase-1b-data-for-xelafaslatide-in-geographic-atrophy 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/how-european-clinicians-are-revolutionizing-retina-care 2025-12-08 0.50 https://www.ophthalmologytimes.com/view/research-supports-iron-dysregulation-may-drive-amd 2025-12-04 0.50 https://www.ophthalmologytimes.com/view/clinical-insights-shaping-real-world-decision-making-in-geographic-atrophy 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/managing-geographic-atrophy-in-a-90-year-old-patient-with-coexisting-neovascular-amd-and-recurrent-cnv-activation 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/evaluating-progressive-multifocal-geographic-atrophy-in-an-asymptomatic-81-year-old-male 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/managing-fovea-threatening-bilateral-geographic-atrophy-in-a-highly-independent-90-year-old-patient 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/advancing-geographic-atrophy-care-early-detection-imaging-innovations-and-evolving-treatment-strategies 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/dual-pathway-inhibition-with-faricimab-differentiating-mechanisms-in-retinal-vascular-diseases 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/understanding-aflibercept-s-structural-design-and-use-of-high-dose-in-retinal-vascular-diseases 2025-12-09 0.50 https://www.ophthalmologytimes.com/view/inflammasome-therapeutics-completes-phase-2-trial-enrollment-for-k8-in-ga 2025-12-04 0.50 https://www.ophthalmologytimes.com/view/the-gene-therapy-shift-a-closer-look-at-the-science-powering-next-generation-retinal-treatments 2025-12-10 0.50 https://www.ophthalmologytimes.com/view/qa-veeral-sheth-personalized-imaging-geographic-atrophy 2026-01-26 0.50 https://www.ophthalmologytimes.com/view/understanding-fluid-fluctuation-in-retinal-disorders 2025-12-08 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-mary-elizabeth-hartnett-rop-research-risk-management 2025-12-11 0.50 https://www.ophthalmologytimes.com/view/from-ai-to-injury-patterns-insights-from-emerging-ophthalmic-research 2025-12-03 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-reframing-retinal-disease-choroidal-health 2025-12-05 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-antithrombotic-use-examined-in-wet-amd-submacular-hemorrhage 2025-12-04 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-navigating-antithrombotic-therapy-in-wet-amd 2025-12-04 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-remotely-managing-patients-with-neovascular-age-related-macular-degeneration 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-rajvardhan-azad-on-bridging-global-gaps-in-rop-care 2025-12-04 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-using-multimodal-imaging-to-rethink-terson-syndrome 2025-12-03 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-multimodal-deep-learning-for-ckd-diagnosis-using-retinal-images-and-urine-dipstick-data 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-weight-and-pma-play-central-roles-in-preterm-foveal-development 2025-12-03 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-port-delivery-system-shows-reliable-6-month-durability-and-sustained-efficacy-in-neovascular-amd-for-up-to-7-years 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-fibrosis-a-limiting-factor-in-visual-acuity-outcomes-in-neovascular-amd 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/floretina-2025-ai-at-the-forefront-of-rop-care 2025-12-03 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-delegates-first-week-of-december-as-5th-annual-geographic-atrophy-week 2025-12-03 0.50 https://www.ophthalmologytimes.com/view/eydenzelt-celltrion-s-biosimilar-referencing-eylea-approved-in-canada 2025-12-03 0.50 https://www.ophthalmologytimes.com/view/aao-2025-takeaways-the-next-frontier-in-retinal-therapeutics-arrives 2025-11-26 0.50 https://www.ophthalmologytimes.com/view/aao-2025-takeaways-how-imaging-and-remote-monitoring-are-transforming-retinal-care 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/corza-medical-announces-launch-of-the-sensortek-rop-kit 2025-12-01 0.50 https://www.ophthalmologytimes.com/view/agc-biologics-to-manufacture-aavantgarde-s-dual-vector-gene-therapies-avb-039-and-aavb-081 2025-11-26 0.50 https://www.ophthalmologytimes.com/view/eyepoint-receives-second-consecutive-positive-recommendation-from-dsmc 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/floretina-congress-celebrates-10-years-with-joint-world-retinopathy-of-prematurity-meeting 2025-11-25 0.50 https://www.ophthalmologytimes.com/view/industry-advances-front-and-center-at-floretina-congress 2025-11-25 0.50 https://www.ophthalmologytimes.com/view/eichenbaum-acorns-inside-the-mindset-of-an-early-adopter 2025-11-24 0.50 https://www.ophthalmologytimes.com/view/lugano-and-lucia-trials-move-forward-unmodified-after-dsmc-review 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/regeneron-s-eylea-hd-injection-8-mg-approved-by-fda-for-the-treatment-of-macular-edema-following-rvo 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents 2025-11-20 0.50 https://www.ophthalmologytimes.com/view/clinical-and-biologic-distinctions-in-managing-retinal-vascular-diseases 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/defining-retinal-vascular-diseases-amd-dme-rvo 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/coave-therapeutics-reveals-lead-gene-therapy-program-cotx-10 2025-11-18 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-releases-4-year-rush2a-data-to-public 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-doses-first-patient-in-phase-1-2-clinical-trial-bird-1-evaluating-opgx-best1 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/q-a-kenneth-fan-on-mco-010-trials-for-stargardt-disease 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/q-a-anat-loewenstein-discusses-the-use-of-home-oct 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/post-hoc-areds2-analysis-highlights-distinct-mechanisms-driving-ga-progression 2025-11-21 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-has-type-b-rmat-meeting-with-fda-for-its-gene-therapy-candidate-opgx-lca5 2025-11-11 0.50 https://www.ophthalmologytimes.com/view/five-year-gale-study-data-announced 2025-11-14 0.50 https://www.ophthalmologytimes.com/view/q-a-diana-do-shares-real-world-insights-on-aflibercept-8-mg 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/polyactiva-and-raresight-partner-to-develop-treatments-for-rare-pediatric-retinal-diseases 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/q-a-stephen-tsang-discusses-outcomes-in-retinitis-pigmentosa-and-stargardt-trials 2025-12-01 0.50 https://www.ophthalmologytimes.com/view/fda-accepts-resubmitted-ons-5010-bla-from-outlook-therapeutics 2025-11-13 0.50 https://www.ophthalmologytimes.com/view/optigo-lead-anti-vegf-program-advancing-toward-ind-enabling-studies 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/q-a-sharon-fekrat-discusses-retinal-manifestations-of-antipsychotic-medications 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/clinical-insights-and-reflections-on-mactel-type-2-management 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/selecting-the-treatment-eye-and-overcoming-implementation-barriers-in-mactel-type-2-management 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/navigating-the-gray-zone-in-mactel-type-2-when-to-treat-early-or-advanced-disease 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/managing-bilateral-mactel-type-2-prioritizing-eye-selection-and-patient-counseling-for-nt-501-implantation-therapy 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/real-world-insights-from-diagnosis-to-treatment-in-macular-telangiectasia-type-2-care 2025-11-12 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-releases-positive-long-term-safety-results-from-extend-study 2025-11-06 0.50 https://www.ophthalmologytimes.com/view/4dmt-releases-positive-interim-1-5--to-3-5-year-data-from-phase-1-2-prism-trial 2025-11-06 0.50 https://www.ophthalmologytimes.com/view/practical-insights-and-shared-experiences-in-managing-geography-atrophy 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/balancing-anti-vegf-and-ga-therapies-for-co-treating-amd-and-ga-in-the-same-eye 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/monocular-high-risk-geographic-atrophy-managing-for-vision-preservation 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/strategies-for-protecting-vision-in-geographic-atrophy 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/aavantgarde-bio-closes-141-million-series-b-financing-round 2025-11-07 0.50 https://www.ophthalmologytimes.com/view/4dmt-and-otsuka-pharmaceutical-partner-on-4d-150-in-the-greater-asia-pacific-region 2025-11-07 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-november-3-to-november-7 2025-11-07 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-reaches-target-enrollment-of-555-patients-in-sol-r-trial 2025-11-07 0.50 https://www.ophthalmologytimes.com/view/optogenetics-for-advanced-retinal-disease 2025-11-07 0.50 https://www.ophthalmologytimes.com/view/sparingvision-doses-first-patient-in-nyrvana-clinical-trial-of-spvn20-for-retinitis-pigmentosa 2025-10-30 0.50 https://www.ophthalmologytimes.com/view/eli-lilly-to-acquire-adverum-biotechnologies 2025-10-30 0.50 https://www.ophthalmologytimes.com/view/anti-vegf-innovations-in-retinal-disease-from-molecules-to-medicine 2025-11-04 0.50 https://www.ophthalmologytimes.com/view/new-data-from-sweden-highlight-lesion-features-that-accelerate-ga-growth 2025-11-04 0.50 https://www.ophthalmologytimes.com/view/the-retina-tl-dr-redefining-office-based-surgery-for-retina-care-with-jonathan-feistmann-md 2025-11-04 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-october-27-to-october-31 2025-10-30 0.50 https://www.ophthalmologytimes.com/view/topcon-healthcare-seeks-to-advance-company-through-acquisition-and-new-investment 2025-11-04 0.50 https://www.ophthalmologytimes.com/view/regeneron-receives-another-crl-for-its-eylea-8-mg 2025-10-30 0.50 https://www.ophthalmologytimes.com/view/research-supports-that-iron-dysregulation-may-drive-amd 2025-11-04 0.50 https://www.ophthalmologytimes.com/view/evolving-strategies-in-retinal-care-navigating-today-s-treatment-landscape 2025-11-06 0.50 https://www.ophthalmologytimes.com/view/onl-therapeutics-randomizes-first-patient-in-phase-2-galaxy-trial-evaluating-xelafaslatide 2025-10-30 0.50 https://www.ophthalmologytimes.com/view/aao-2025-the-safety-and-efficacy-of-oral-gildeuretinol-in-participants-with-intermediate-stage-stargardt-disease 2025-10-23 0.50 https://www.ophthalmologytimes.com/view/pipeline-update-catch-up-on-recent-updates-in-the-retina-pipeline 2025-10-30 0.50 https://www.ophthalmologytimes.com/view/geographic-atrophy-in-amd-and-namd-patients-real-world-management-challenges-and-strategies 2025-10-27 0.50 https://www.ophthalmologytimes.com/view/study-establishes-reference-data-set-for-ga-lesion-progression 2025-10-23 0.50 https://www.ophthalmologytimes.com/view/belite-bio-announces-nda-acceptance-of-tinlarbant-by-china-s-nmpa 2025-10-22 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-october-20-to-october-24 2025-10-23 0.50 https://www.ophthalmologytimes.com/view/retinoblastoma-decreasing-mortality-morbidity-and-enucleation 2025-10-23 0.50 https://www.ophthalmologytimes.com/view/sydnexis-receives-crl-from-the-fda-for-its-syd-101-pediatric-myopia-drug 2025-10-24 0.50 https://www.ophthalmologytimes.com/view/aao-2025-trial-findings-apply-gildeuretinol-to-treat-moderate-severity-stargardt-disease-phase-2-tease 2025-10-21 0.50 https://www.ophthalmologytimes.com/view/aao-2025-anatomic-and-functional-outcomes-geographic-atrophy-pegcetacoplan-in-gale-extension-study 2025-10-21 0.50 https://www.ophthalmologytimes.com/view/rounding-up-the-top-news-stories-from-aao-2025 2025-10-21 0.50 https://www.ophthalmologytimes.com/view/domp-s-naion-program-selected-for-fda-commissioner-s-national-priority-voucher-program 2025-10-21 0.50 https://www.ophthalmologytimes.com/view/fda-approves-glaukos-epioxa-incision-free-keratoconus-therapy 2025-10-21 0.50 https://www.ophthalmologytimes.com/view/current-and-emerging-treatments-for-geographic-atrophy-and-when-to-initiate-therapy 2025-10-20 0.50 https://www.ophthalmologytimes.com/view/aao-2025-subretinal-drusenoid-deposits-in-black-and-hispanic-patients-with-amd 2025-10-28 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-details-phase-3-program-evaluating-vorolanib-intravitreal-insert-duravyu-for-dme 2025-10-17 0.50 https://www.ophthalmologytimes.com/view/inder-paul-singh-md-reports-his-clinical-experience-with-the-academy-technician-training-platform 2025-10-16 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-october-13-to-october-17 2025-10-17 0.50 https://www.ophthalmologytimes.com/view/empowerment-through-education-q-a-with-inder-paul-singh-md 2025-10-16 0.50 https://www.ophthalmologytimes.com/view/aao-2025-ashkan-abbey-on-the-outcomes-of-eyp-1901-for-amd-and-dme 2025-10-16 0.50 https://www.ophthalmologytimes.com/view/abeona-therapeutics-abo-503-chosen-for-fda-s-rare-disease-endpoint-advancement-pilot-program 2025-10-13 0.50 https://www.ophthalmologytimes.com/view/leadership-in-action-during-the-2025-aao-named-lectures 2025-10-16 0.50 https://www.ophthalmologytimes.com/view/quantifying-intermittent-retinal-capillary-perfusion-in-rvo-and-pdr 2025-10-10 0.50 https://www.ophthalmologytimes.com/view/aao-debuts-technician-training-platform-ahead-of-2025-meeting 2025-10-15 0.50 https://www.ophthalmologytimes.com/view/increasing-the-knowledge-base-of-ga-is-key-to-individualizing-patient-therapy 2025-10-09 0.50 https://www.ophthalmologytimes.com/view/study-finds-retinal-progenitor-cell-injections-improve-outcomes-in-rat-model-of-diabetic-retinopathy 2025-10-08 0.50 https://www.ophthalmologytimes.com/view/advancing-sustained-vegf-suppression-with-eyp-1901-with-jay-s-duker-md 2025-10-13 0.50 https://www.ophthalmologytimes.com/view/frank-holz-highlights-new-treatment-developments-at-euretina 2025-10-13 0.50 https://www.ophthalmologytimes.com/view/challenges-reported-by-young-physicians-in-managing-geographic-atrophy-and-how-these-shape-patient-care 2025-10-15 0.50 https://www.ophthalmologytimes.com/view/q-a-the-archer-trial-and-the-importance-of-continued-ga-research 2025-10-14 0.50 https://www.ophthalmologytimes.com/view/q-a-what-is-the-value-of-the-yours-program-at-euretina- 2025-10-14 0.50 https://www.ophthalmologytimes.com/view/kristina-pfau-md-febo-discusses-her-research-using-high-resolution-oct-to-examine-pxe-patients-and-more 2025-10-10 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-october-6-to-october-10 2025-10-10 0.50 https://www.ophthalmologytimes.com/view/peter-kaiser-md-discusses-otx-tki-a-new-treatment-for-wet-amd-introduced-by-ocular-therapeutics 2025-10-14 0.50 https://www.ophthalmologytimes.com/view/eydenzelt-celltrion-s-biosimilar-referencing-eylea-approved-by-fda 2025-10-14 0.50 https://www.ophthalmologytimes.com/view/part-6-kol-reflections-on-what-they-would-say-to-retina-fellows 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/broader-perspective-for-the-treatment-approach-on-retinal-neovascular-diseases 2025-10-07 0.50 https://www.ophthalmologytimes.com/view/nadia-waheed-md-mph-transforming-retinal-disease-imaging-and-clinical-trials 2025-10-16 0.50 https://www.ophthalmologytimes.com/view/jay-chhablani-md-reviews-late-breaking-findings-from-the-armada-trial 2025-10-09 0.50 https://www.ophthalmologytimes.com/view/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-in-wet-amd 2025-10-09 0.50 https://www.ophthalmologytimes.com/view/charles-miller-md-phd-on-dme-research-and-the-initiation-of-the-phase-2b-3-brunello-trial 2025-10-22 0.50 https://www.ophthalmologytimes.com/view/fda-clears-ind-for-complement-therapeutics-ctx001-gene-therapy-in-geographic-atrophy 2025-10-09 0.50 https://www.ophthalmologytimes.com/view/patricio-schlottmann-md-highlights-4-year-extension-data-during-euretina-2025 2025-10-08 0.50 https://www.ophthalmologytimes.com/view/aavantgarde-s-aavb-039-gene-therapy-to-treat-stargardt-disease-receives-orphan-drug-status-from-fda 2025-10-09 0.50 https://www.ophthalmologytimes.com/view/aao-2025-imagine-what-can-happen-during-this-collective-experience 2025-10-06 0.50 https://www.ophthalmologytimes.com/view/fda-grants-breakthrough-therapy-designation-to-nacuity-s-npi-001-for-retinitis-pigmentosa 2025-10-09 0.50 https://www.ophthalmologytimes.com/view/intravitreal-complement-inhibitor-treatment-for-ga-viewed-favorably-by-patients 2025-10-07 0.50 https://www.ophthalmologytimes.com/view/aao-2025-what-the-eye-care-network-s-editorial-advisory-board-members-are-presenting 2025-10-07 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-september-29-to-october-3 2025-10-03 0.50 https://www.ophthalmologytimes.com/view/euretina-honors-young-researcher-with-ramin-tadayoni-memorial-award 2025-10-02 0.50 https://www.ophthalmologytimes.com/view/two-experts-present-on-acute-optic-neuritis-and-the-acuity-trial-during-euretina-2025-oculis-ocs-05 2025-10-02 0.50 https://www.ophthalmologytimes.com/view/eichenbaum-acorns-a-leadership-conversation-with-rishi-p-singh-md-fasrs-on-advancing-cme 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/positive-pediatric-data-emerge-from-the-opgx-lca5-phase-1-2-trial-of-leber-congenital-amaurosis-type-5 2025-10-07 0.50 https://www.ophthalmologytimes.com/view/navigating-the-maze-establishing-novel-endpoints-for-ird-trials 2026-02-26 0.50 https://www.ophthalmologytimes.com/view/part-5-kol-reflections-on-what-they-would-say-to-retina-fellows 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/anniversary-of-the-spectral-oct-prototype-25-years-young-and-growing 2025-09-30 0.50 https://www.ophthalmologytimes.com/view/staar-and-broadwood-clash-over-proposed-alcon-merger 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/q-a-christine-kay-on-the-remain-trial-results-for-patients-with-retinitis-pigmentosa 2025-10-01 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-maria-berrocal-md-discusses-the-vit-buckle-society 2025-09-25 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-september-22-to-september-26 2025-09-26 0.50 https://www.ophthalmologytimes.com/view/isth0036-shows-promise-in-treating-retinal-diseases 2025-09-25 0.50 https://www.ophthalmologytimes.com/view/macumira-launches-first-health-canada-approved-device-for-amd-treatment 2025-09-30 0.50 https://www.ophthalmologytimes.com/view/anat-loewenstein-md-shares-highlights-from-euretina-2025 2025-09-24 0.50 https://www.ophthalmologytimes.com/view/idebenone-accepted-by-fda-for-priority-review-for-leber-hereditary-optic-neuropathy 2025-09-25 0.50 https://www.ophthalmologytimes.com/view/staar-surgical-confirms-expiration-of-window-shop-period-in-alcon-merger-agreement 2025-09-25 0.50 https://www.ophthalmologytimes.com/view/part-4-kol-reflections-on-what-they-would-say-to-retina-fellows 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/luxa-biotechnology-announces-clinical-trial-results-for-treatment-of-amd 2025-09-25 0.50 https://www.ophthalmologytimes.com/view/conavi-medical-submits-novasight-hybrid-ivus-oct-system-to-fda-for-510-k-clearance 2025-09-25 0.50 https://www.ophthalmologytimes.com/view/character-biosciences-expands-leadership-team-secures-additional-series-b-financing 2025-09-22 0.50 https://www.ophthalmologytimes.com/view/oct-imaging-moves-beyond-the-macula-peripheral-retina-at-the-2025-euretina-congress-daniela-bacherini 2025-09-22 0.50 https://www.ophthalmologytimes.com/view/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-eyluxvi-alt-l9- 2025-09-19 0.50 https://www.ophthalmologytimes.com/view/q-a-justis-p-ehlers-md-on-the-phase-1-helios-trial-for-npdr 2025-09-23 0.50 https://www.ophthalmologytimes.com/view/kalaris-enrolling-phase-1b-2-study-of-th103-for-namd 2025-09-23 0.50 https://www.ophthalmologytimes.com/view/norway-first-in-world-to-deploy-autonomous-ai-eye-screening-technology-on-national-scale 2025-09-23 0.50 https://www.ophthalmologytimes.com/view/part-3-kol-reflections-on-what-they-would-say-to-retina-fellows 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-september-15-to-september-19 2025-09-19 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-the-changing-face-of-clinical-endpoints-in-age-related-macular-degeneration-amd-trials 2025-09-19 0.50 https://www.ophthalmologytimes.com/view/ollin-biosciences-announces-its-official-launch 2025-09-18 0.50 https://www.ophthalmologytimes.com/view/kodiak-announces-new-data-from-apex-study-of-ksi-101 2025-09-16 0.50 https://www.ophthalmologytimes.com/view/inflammasome-inhibitor-found-to-reduce-ga-lesion-area-growth-in-clinical-study 2025-09-18 0.50 https://www.ophthalmologytimes.com/view/staar-surgical-files-definitive-proxy-statement-on-pending-merger-with-alcon 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/status-of-the-inner-retinal-layers-in-patients-with-multiple-sclerosis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/belite-bio-concludes-phase-3-dragon-study-for-stargardt-disease 2025-09-18 0.50 https://www.ophthalmologytimes.com/view/ocugen-kwangdong-complete-licensing-agreement-for-ocu400-gene-therapy-in-korea 2025-09-15 0.50 https://www.ophthalmologytimes.com/view/part-2-kol-reflections-on-what-they-would-say-to-retina-fellows 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/optain-health-secures-26-million-series-a-funding 2025-09-18 0.50 https://www.ophthalmologytimes.com/view/andreas-pollreisz-md-encourages-taking-a-second-look-with-oct-a-euretina-congress-diabetic-retinopathy-edema 2025-09-12 0.50 https://www.ophthalmologytimes.com/view/new-study-examines-soft-drusen-regression-without-atrophy-and-drusen-ooze 2025-09-16 0.50 https://www.ophthalmologytimes.com/view/new-company-opzira-formed-following-alcon-s-acquisition-of-lumithera 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/university-of-houston-researchers-receive-3-6-million-to-examine-retinal-diseases 2025-09-16 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-september-8-to-september-12 2025-09-12 0.50 https://www.ophthalmologytimes.com/view/q-a-amir-kashani-on-biomarkers-for-alzheimer-disease 2025-09-16 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-why-the-current-staging-for-diabetic-eye-disease-is-obsolete-stela-vujosevic 2025-09-12 0.50 https://www.ophthalmologytimes.com/view/study-links-amd-to-higher-cardiovascular-disease-mortality-in-high-risk-patients 2025-09-16 0.50 https://www.ophthalmologytimes.com/view/sar402663-earns-fast-track-designation-for-treatment-of-namd 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/harvey-uy-md-dpbo-fvrsp-says-ai-artificial-intelligence-brings-a-fifth-dimension-to-retina-care 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/glp-1ras-associated-with-reduction-in-uveitis-development-risk-in-new-study 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/sandoz-and-regeneron-reach-agreement-over-biosimilar-dispute 2025-09-10 0.50 https://www.ophthalmologytimes.com/view/diabetic-retinopathy-in-pregnancy 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/alcon-completes-acquisition-of-lumithera 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/part-1-kol-reflections-on-what-they-would-say-to-retina-fellows 2025-11-10 0.50 https://www.ophthalmologytimes.com/view/a-study-of-the-progression-of-sensitivity-loss-in-ga-over-time-using-inferred-data 2025-09-11 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-peter-kiraly-phd-helps-young-retinal-specialists-break-into-the-vitreoretinal-space-surgery-training-yours-program 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-announces-positive-topline-data-from-dawn-and-skyline-trials 2025-09-09 0.50 https://www.ophthalmologytimes.com/view/the-retina-tl-dr-rethinking-retinal-detachment-repair 2025-09-29 0.50 https://www.ophthalmologytimes.com/view/new-insights-show-later-is-better-for-some-lhon-interventions 2025-09-09 0.50 https://www.ophthalmologytimes.com/view/eyecool-therapeutics-appoints-vance-thompson-md-to-board-of-directors 2025-09-03 0.50 https://www.ophthalmologytimes.com/view/giuseppe-querques-md-phd-euretina-telcaps-pvac-perifoveal-vascular-anomalous-complex-telangiectatic-capillaries 2025-09-06 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-sofia-androudi-on-retinal-disorders-mimicking-inherited-retinal-diseases 2025-09-10 0.50 https://www.ophthalmologytimes.com/view/treating-ophthalmic-artery-stenosis-in-geographic-atrophy-with-angioplasty 2025-09-03 0.50 https://www.ophthalmologytimes.com/view/keynote-speaker-maria-vittoria-cicinelli-md-febo-clinicians-should-white-spot-syndrome-ophthalmologica-lecture 2025-09-05 0.50 https://www.ophthalmologytimes.com/view/jean-francois-korobelnik-md-says-surgeons-are-under-utilizing-a-key-surgical-tool-gisbert-richard-keynote-lecture-euretina 2025-09-22 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-kreissig-award-lecture-throwing-away-wisdom-how-we-abandon-what-works 2025-09-09 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-elon-van-dijk-on-central-serous-chorioretinopathy 2025-09-05 0.50 https://www.ophthalmologytimes.com/view/dont-miss-the-women-in-retina-networking-breakfast-at-euretina 2025-09-05 0.50 https://www.ophthalmologytimes.com/view/neurotech-pharmaceuticals-appoints-peter-j-mcdonnell-md-to-board-of-directors 2025-09-03 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-timothy-lai-discusses-the-salween-1-year-data 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/progression-rates-vary-in-subtypes-of-geographic-atrophy-lesions 2025-08-29 0.50 https://www.ophthalmologytimes.com/view/contivue-port-delivery-platform-for-namd-receives-ce-mark 2025-09-09 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-aleksandra-rachitskaya-and-danilo-ianetta-on-the-vit-buckle-symposium 2025-09-10 0.50 https://www.ophthalmologytimes.com/view/ashvattha-announces-positive-topline-data-for-mgb-for-the-treatment-of-dme-and-namd 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/euretina-2025-marion-munk-md-phd-discusses-the-intris-symposium 2025-09-10 0.50 https://www.ophthalmologytimes.com/view/ursula-schmidt-erfurth-md-discusses-her-keynote-euretina-lecture-amd-ai 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/euretina-leadership-welcome-party-networking-clinical-education-presentation-record-breaking-number-of-attendees 2025-09-03 0.50 https://www.ophthalmologytimes.com/view/euretina-honors-late-president-with-second-annual-ramin-tadayoni-award 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/pulsesight-to-highlight-new-data-on-the-role-of-iron-and-transferrin-in-amd-at-euretina-2025 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/bvi-unveils-new-virtuoso-surgical-platform 2025-09-09 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-requests-type-a-meeting-with-fda-following-second-crl-for-ons-5010 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/the-eye-care-network-s-clinical-advisors-will-present-at-euretina 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/euretina-innovation-spotlight-kickstarts-the-2025-congress-eis-paris-france-anat-loewenstein 2025-09-02 0.50 https://www.ophthalmologytimes.com/view/aavantgarde-ocular-therapeutix-oculis-announce-euretina-presentations 2025-09-02 0.50 https://www.ophthalmologytimes.com/view/starting-from-scratch-on-neovascular-age-related-macular-degeneration 2025-08-26 0.50 https://www.ophthalmologytimes.com/view/q-a-vicky-demas-on-the-value-of-easy-to-use-imaging-tools-and-the-potential-of-ai 2025-09-03 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-implements-diabetes-the-eyes-advisory-committee-to-combat-diabetes-related-eye-diseases 2025-08-26 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-august-25-to-august-29 2025-08-29 0.50 https://www.ophthalmologytimes.com/view/fda-issues-complete-response-letter-to-outlook-therapeutics-for-resubmitted-bla-for-ons-5010 2025-08-28 0.50 https://www.ophthalmologytimes.com/view/xlrp-rp-and-wet-amd-trial-data-slotted-for-presentation-at-euretina-2025 2025-08-29 0.50 https://www.ophthalmologytimes.com/view/researchers-examine-brain-immune-cell-impact-on-the-eye 2025-08-26 0.50 https://www.ophthalmologytimes.com/view/upcoming-euretina-2025-presentations-from-clearside-zeiss-and-ashvattha 2025-08-28 0.50 https://www.ophthalmologytimes.com/view/european-commission-approves-aflibercept-biosimilar-mynzepli 2025-08-25 0.50 https://www.ophthalmologytimes.com/view/study-establishes-reference-data-set-for-geographic-atrophy-lesion-progression 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/fda-extends-target-action-date-for-two-regeneron-regulatory-submissions-to-q4-of-2025 2025-08-25 0.50 https://www.ophthalmologytimes.com/view/eye-care-network-ophthalmology-times-europe-editorial-board-2025-euretina-congress-paris 2025-08-26 0.50 https://www.ophthalmologytimes.com/view/cannabis-may-protect-against-postoperative-proliferative-vitreoretinopathy-development 2025-08-26 0.50 https://www.ophthalmologytimes.com/view/q-a-daniela-ferrara-on-the-potential-of-ai-in-retina 2025-08-26 0.50 https://www.ophthalmologytimes.com/view/knowing-when-the-diamond-dusted-membrane-scraper-is-and-isn-t-the-right-tool 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/euretina-25th-annual-congress-european-society-retina-specialists-paris-france-2025 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/kriya-therapeutics-raises-313-3-million-in-funding 2025-08-25 0.50 https://www.ophthalmologytimes.com/view/q-a-vivienne-s-hau-md-phd-discusses-racial-and-ethnic-disparities-in-retinoblastoma-treatment-options 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/from-bench-to-bedside-evolving-realities-of-gene-therapy-for-inherited-retinal-diseases 2025-08-25 0.50 https://www.ophthalmologytimes.com/view/an-eye-on-how-patients-perceive-their-retinal-diseases 2025-08-25 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-august-18-to-august-22 2025-08-22 0.50 https://www.ophthalmologytimes.com/view/q-a-danny-a-mammo-md-on-the-associations-between-androgen-exposure-pcos-and-transmasculine-individuals-with-central-serous-chorioretinopathy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/q-a-andrew-j-barkmeier-md-on-the-risk-of-sight-threatening-diabetic-retinopathy-with-glp-1-ra-use 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/q-a-sally-s-ong-md-on-the-neighborhood-level-characteristics-associated-with-delay-in-surgery-and-loss-to-follow-up 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/improving-vitrectomy-outcomes-and-patient-care-in-academic-and-private-settings 2025-08-25 0.50 https://www.ophthalmologytimes.com/view/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-for-inherited-retinal-disease 2025-08-22 0.50 https://www.ophthalmologytimes.com/view/encouraging-a-preservation-mindset-in-ga-overcoming-hesitation-and-embracing-innovation 2025-08-20 0.50 https://www.ophthalmologytimes.com/view/measuring-success-in-ga-treatment-beyond-immediate-vision-gains 2025-08-20 0.50 https://www.ophthalmologytimes.com/view/first-patients-dosed-in-jc02-88-study 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-geographic-atrophy-on-display 2025-08-18 0.50 https://www.ophthalmologytimes.com/view/navigating-the-most-recent-fda-approvals-in-retina 2025-09-04 0.50 https://www.ophthalmologytimes.com/view/multidisciplinary-insights-into-diagnosing-tubulointerstitial-nephritis-uveitis 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/q-a-david-liao-md-phd-presents-the-extended-efficacy-and-safety-of-mco-010-for-rp 2025-08-21 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-august-11-to-august-15 2025-08-18 0.50 https://www.ophthalmologytimes.com/view/improving-patient-experience-with-intravitreal-injections 2025-08-27 0.50 https://www.ophthalmologytimes.com/view/q-a-ella-h-leung-md-explains-the-economic-impact-of-anti-vegf-prior-authorization-process 2025-08-14 0.50 https://www.ophthalmologytimes.com/view/study-identifies-electroretinography-pupillometry-as-top-predictor-of-dr-progression-vision-threatening-complications 2025-08-22 0.50 https://www.ophthalmologytimes.com/view/lupin-and-sandoz-sign-licensing-deal-for-biosimilar-ranibizumab-across-multiple-regions 2025-08-13 0.50 https://www.ophthalmologytimes.com/view/q-a-david-eichenbaum-md-on-the-archer-2-study-for-dry-amd-and-ga 2025-08-14 0.50 https://www.ophthalmologytimes.com/view/q-a-roger-a-goldberg-on-the-48-month-results-from-oaks-derby-and-gale-open-label-extension 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/can-ai-explain-amd-to-patients- 2025-08-13 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-secures-fda-spa-agreement-for-axpaxli-registrational-trial 2025-08-13 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-a-post-hoc-analysis-of-the-effect-of-baseline-ez-layer-loss-on-treatment-outcomes-in-mactel 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/considerations-for-incorporating-ga-therapies-into-clinical-practice 2025-08-13 0.50 https://www.ophthalmologytimes.com/view/assessing-benefit-risk-profile-of-ga-therapies 2025-08-13 0.50 https://www.ophthalmologytimes.com/view/managing-and-tracking-the-worldwide-burden-of-retinoblastoma 2025-08-14 0.50 https://www.ophthalmologytimes.com/view/a-realistic-outlook-on-diabetes-remission-glp-1-therapies-diabetic-retinopathy-s-future 2025-08-14 0.50 https://www.ophthalmologytimes.com/view/first-fda-approved-mactel-treatment-performed 2025-08-15 0.50 https://www.ophthalmologytimes.com/view/regenxbio-announces-phase-2b-3-trial-for-sura-vec 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/an-implantable-solution-fills-the-treatment-gap-for-amd-patients 2025-08-22 0.50 https://www.ophthalmologytimes.com/view/nice-approves-idebenone-for-treating-lhon 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/parental-delay-largely-causes-late-retinoblastoma-diagnosis-treatment- 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-outcomes-in-patients-with-noninfectious-uveitis-requiring-secondary-lens-implantation 2025-08-09 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-august-4-to-august-8 2025-08-08 0.50 https://www.ophthalmologytimes.com/view/q-a-alan-j-franklin-md-phd-on-postoperative-methotrexate-injections 2025-08-09 0.50 https://www.ophthalmologytimes.com/view/4dmt-reports-positive-spectra-results-in-dme-trial 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/q-a-jennifer-i-lim-md-shares-insights-from-the-davio-2-study 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/exploratory-analysis-identifies-predictors-of-improved-bcva-in-lhon- 2025-08-12 0.50 https://www.ophthalmologytimes.com/view/choosing-between-the-currently-available-ga-therapies 2025-08-06 0.50 https://www.ophthalmologytimes.com/view/evolving-approaches-to-ga-management-in-the-era-of-complement-inhibitors 2025-08-06 0.50 https://www.ophthalmologytimes.com/view/q-a-jay-chhablani-md-on-the-phase-1-2-data-for-ocu410-from-asrs-2025 2025-08-04 0.50 https://www.ophthalmologytimes.com/view/q-a-matthew-starr-md-shares-his-experience-using-scleral-suture-toric-intraocular-lenses-for-patients-with-significant-corneal-astigmatism 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-underfunding-of-good-days-program-affect-on-patients-and-practices 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aac-announces-updated-clinical-trial-protocol 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/five-year-data-announced-from-phase-3-portal-study 2025-08-05 0.50 https://www.ophthalmologytimes.com/view/health-canada-approves-clearside-biomedical-s-xipere 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-per-001-improved-structure-and-visual-function-in-patients-with-diabetic-retinopathy 2025-08-05 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-an-analysis-of-patients-who-received-pegcetacoplan-and-anti-vegf-for-ga 2025-08-01 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-an-association-of-vitamin-d-insufficiency-with-proliferative-vitreoretinopathy 2025-08-05 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-july-28-to-august-1 2025-08-01 0.50 https://www.ophthalmologytimes.com/view/q-a-24-month-results-of-the-phase-2-skyline-trial-for-xlrp 2025-08-08 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-end-of-study-results-from-verona-a-phase-2-trial-of-eyp-1901 2025-07-31 0.50 https://www.ophthalmologytimes.com/view/christina-y-weng-md-mba-fasrs-shares-an-overview-of-her-asrs-2025-presentation 2025-08-05 0.50 https://www.ophthalmologytimes.com/view/retinal-microvasculature-on-octa-may-predict-coronary-artery-disease-risk 2025-07-31 0.50 https://www.ophthalmologytimes.com/view/q-a-andrew-g-lee-md-shares-what-every-retina-specialist-should-know-about-neuro-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/q-a-a-look-at-suprachoroidal-avoralstat-with-dilsher-s-dhoot-at-asrs-2025 2025-07-31 0.50 https://www.ophthalmologytimes.com/view/topcon-acquires-iris-enhances-ai-eye-screenings 2025-08-01 0.50 https://www.ophthalmologytimes.com/view/helping-patients-understand-the-urgency-of-early-action-in-geographic-atrophy 2025-07-30 0.50 https://www.ophthalmologytimes.com/view/eyepoint-completes-enrollment-of-lugano-and-lucia-trials 2025-08-01 0.50 https://www.ophthalmologytimes.com/view/clinical-variability-in-ga-and-the-role-of-imaging-in-diagnosis-and-monitoring 2025-07-30 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-and-global-rdh12-alliance-announce-partnership 2025-08-01 0.50 https://www.ophthalmologytimes.com/view/alcon-presenting-new-retina-tools-clinical-data-at-asrs 2025-07-29 0.50 https://www.ophthalmologytimes.com/view/chmp-issues-positive-opinion-for-alteogen-s-aflibercept-biosimilar-eyluxvi 2025-07-29 0.50 https://www.ophthalmologytimes.com/view/asrs-2025-what-to-expect-in-long-beach-california 2025-07-29 0.50 https://www.ophthalmologytimes.com/view/re-vana-and-boehringer-ingelheim-enter-1b-collaboration-to-advance-sustained-release-eye-therapies 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/propelling-r-d-for-novel-retinal-therapies-through-innovative-clinical-trial-design 2025-07-24 0.50 https://www.ophthalmologytimes.com/view/scuba-divers-and-surfers-face-dual-light-exposure-that-may-accelerate-amd 2025-07-25 0.50 https://www.ophthalmologytimes.com/view/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-geographic-atrophy 2025-07-25 0.50 https://www.ophthalmologytimes.com/view/new-day-trial-of-iluvien-for-dme-does-not-meet-primary-endpoint-post-hoc-analysis-suggests-potential-benefits 2025-07-29 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-july-21-to-july-25 2025-07-25 0.50 https://www.ophthalmologytimes.com/view/adx-2191-receives-em-orphan-drug-designation-for-inherited-retinal-dystrophies 2025-07-29 0.50 https://www.ophthalmologytimes.com/view/ai-powered-eye2gene-uses-multimodal-imaging-to-diagnose-inherited-retinal-disease 2025-07-23 0.50 https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-receives-patent-for-kio-104 2025-07-29 0.50 https://www.ophthalmologytimes.com/view/evaluating-chatgpt-4o-s-ability-to-generate-reliable-retinal-fundus-images 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-announces-upcoming-conference-presentations 2025-07-25 0.50 https://www.ophthalmologytimes.com/view/role-of-mucormycosis-infection-on-vision-in-diabetic-patient 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocugen-announces-new-sab-members-and-leadership-changes 2025-07-25 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-july-14-to-july-18 2025-07-18 0.50 https://www.ophthalmologytimes.com/view/moran-eye-center-researcher-plays-role-in-ai-use-in-eye-care 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/could-targeting-retinal-non-perfusion-be-the-key-to-achieving-true-disease-modification-in-diabetic-retinopathy 2025-07-17 0.50 https://www.ophthalmologytimes.com/view/aavantgarde-bio-receives-ind-clearance-for-aavb-039 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/fda-grants-fast-track-designation-to-sar446597 2025-07-18 0.50 https://www.ophthalmologytimes.com/view/impending-us-trade-tariffs-may-upend-optical-industry-stability 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-grants-nanoscope-rolling-bla-submission-of-mco-010 2025-07-17 0.50 https://www.ophthalmologytimes.com/view/real-world-insights-with-eylea-8mg 2025-07-11 0.50 https://www.ophthalmologytimes.com/view/retinalgenix-technologies-contracts-labcorp-to-support-on-dna-rna-gps-pharmaco-genetic-mapping-platform 2025-07-15 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-july-7-to-july-11 2025-07-10 0.50 https://www.ophthalmologytimes.com/view/study-links-cannabis-use-to-lower-risk-of-proliferative-vitreoretinopathy-after-retinal-detachment-repair 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/comparing-vorolanib-intravitreal-insert-with-aflibercept-in-dme-treatment 2025-07-08 0.50 https://www.ophthalmologytimes.com/view/enrollment-complete-for-beacon-therapeutics-phase-2-3-vista-trial 2025-07-15 0.50 https://www.ophthalmologytimes.com/view/fda-agrees-to-expand-atsena-s-gene-therapy-trial-for-xlrs-treatment 2025-07-10 0.50 https://www.ophthalmologytimes.com/view/reducing-site-burden-and-expanding-research-capacity-with-ai 2025-07-07 0.50 https://www.ophthalmologytimes.com/view/exposure-to-pesticides-and-increased-risk-of-amd 2025-07-07 0.50 https://www.ophthalmologytimes.com/view/a-review-of-the-davio-2-phase-2-trial-results 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/alcon-to-acquire-lumithera-and-its-photobiomodulation-device-for-the-treatment-of-dry-amd 2025-07-07 0.50 https://www.ophthalmologytimes.com/view/multiple-intravitreal-injections-and-their-effect-on-the-optic-nerve-head-in-patients-with-crvo 2025-07-01 0.50 https://www.ophthalmologytimes.com/view/thulite-phase-ii-study-evaluates-bi-1815368 2025-07-15 0.50 https://www.ophthalmologytimes.com/view/highlights-from-arvo-2025 2025-07-01 0.50 https://www.ophthalmologytimes.com/view/intravitreal-implant-shows-potential-for-treating-the-root-causes-of-glaucoma-and-diabetic-retinopathy 2025-07-01 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-june-30-to-july-4 2025-07-01 0.50 https://www.ophthalmologytimes.com/view/iridex-enrolls-first-patient-in-study-evaluating-micropulse-technology-as-an-adjunct-to-anti-vegf-therapy-for-dme 2025-06-30 0.50 https://www.ophthalmologytimes.com/view/improving-retinal-drying-and-treatment-durability-with-second-generation-anti-vegf-therapies 2025-06-30 0.50 https://www.ophthalmologytimes.com/view/most-patients-support-ai-in-healthcare-if-it-means-more-time-with-doctors 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/the-future-promise-of-advanced-therapies-in-ophthalmology 2025-06-30 0.50 https://www.ophthalmologytimes.com/view/retinal-degeneration-fund-providing-funding-to-opus-genetics-to-support-opgx-mertk-program 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/drugs-to-treat-ga-yes-please- 2025-06-27 0.50 https://www.ophthalmologytimes.com/view/nanoscope-announces-formation-of-vision-advisory-committee 2025-06-26 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-june-23-to-june-27 2025-06-27 0.50 https://www.ophthalmologytimes.com/view/cts-2025-christine-kay-md-on-opgx-lca5-clinical-results-translated-into-real-life-changes 2025-06-28 0.50 https://www.ophthalmologytimes.com/view/advancing-ocular-pharmacotherapy-through-the-suprachoroidal-space 2025-06-26 0.50 https://www.ophthalmologytimes.com/view/pyc-works-to-meet-fda-alignment-for-its-investigational-drug-candidate-vp-001 2025-06-25 0.50 https://www.ophthalmologytimes.com/view/successful-phase-1b-study-of-oral-therapy-for-diabetic-retinopathy 2025-06-30 0.50 https://www.ophthalmologytimes.com/view/how-remote-retinal-imaging-raises-the-bar-across-service-research-and-education 2025-06-23 0.50 https://www.ophthalmologytimes.com/view/pearls-for-engaging-in-clinical-trials 2025-06-23 0.50 https://www.ophthalmologytimes.com/view/q-a-meeting-the-need-for-low-vision-services-with-wearable-tech 2025-06-19 0.50 https://www.ophthalmologytimes.com/view/next-generation-retinal-disease-treatments-advancing-care-in-namd-and-dme 2025-06-17 0.50 https://www.ophthalmologytimes.com/view/ruth-hogg-phd-on-what-retinal-imaging-can-tell-clinicians-about-the-brain-and-body 2025-06-19 0.50 https://www.ophthalmologytimes.com/view/victor-gonzalez-md-shares-research-findings-on-vision-restoration-in-patients-with-retinitis-pigmentosa-clinical-trials-summit 2025-06-20 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-june-16-to-june-20 2025-06-19 0.50 https://www.ophthalmologytimes.com/view/ocugen-s-ind-amendment-to-begin-phase-2-3-confirmatory-trial-of-ocu410st-cleared-by-fda 2025-06-19 0.50 https://www.ophthalmologytimes.com/view/genetic-link-found-between-instant-coffee-consumption-and-dry-amd 2025-06-19 0.50 https://www.ophthalmologytimes.com/view/nasa-scientist-steven-laurie-phd-on-extreme-telemedicine-during-long-duration-spaceflight 2025-06-16 0.50 https://www.ophthalmologytimes.com/view/eyestem-completes-phase-1-study-of-eyecyte-rpe-in-patients-with-geographic-atrophy 2025-06-19 0.50 https://www.ophthalmologytimes.com/view/q-a-arshad-m-khanani-md-ma-fasrs-on-the-cts-2025-meeting 2025-06-18 0.50